Pular para o conteúdo principal
Ranking Invest

ABVX - Abivax S.A.

Segmento: HealthcareABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.

Análise Ranking Invest

Valor de Mercado
$ 7.62 Bi
IVR
-0.05Índice proprietário de comparação relativa: -0,05.
IVR2
-0.05Leitura proprietária complementar: -5%.
MLL
-0.05Leitura proprietária complementar: -5%.
Último Balanço Atualizado: 4T2024

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 40.58 Mi

Dívida Líquida

-$ 35.00 Mi

L4T

-$ 235.86 Mi

MM4T

-2203.25%

Indicadores Básicos

ROE

-581.17%

Índices de Previsibilidade

Receita Líquida

G1.99

Lucro

D0.57

Margem

D0.91

Índices de Tendência

Receita Líquida

B9.82

Lucro

G-9.63

Margem

E-3.32

Índices de Endividamento

DIV/PAT

-0.86

DIV/L4T

0.15

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.